Subcutaneous and Deep Fungus Infections

  • Pietro NenoffEmail author
  • Mohamed Taha
  • Peter Mugisha


Moulds and yeasts, so-called dimorphic fungi, cause a number of cutaneous infections. Transmission takes place via inoculation of the agents as a result of injury, e.g. following barefoot walking in semiarid to arid areas, or through haematogenous spread, mostly from the lung. Examples for inoculation mycoses are mycetomas caused by various fungi and bacteria, chromoblastomycoses due to melanized or brown-pigmented fungi and sporotrichosis due to Sporothrix schenckii, a ubiquitous occurring dimorphic fungus. Secondary cutaneous involvement after haematogenous transmission occurs in blastomycosis, coccidioidomycosis, cryptococcosis and histoplasmosis, frequently in immunosuppressed patients.


  1. 1.
    Mitjà O, Marks M, Bertran L, et al. Integrated control and management of neglected tropical skin diseases. PLoS Negl Trop Dis. 2017;11:e0005136.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Zijlstra EE, van de Sande WW, Fahal AH. Mycetoma: a long journey from neglect. PLoS Negl Trop Dis. 2016;10:e0004244.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Al-Hatmi AM, Bonifaz A, Tirado-Sánchez A, et al. Fusarium species causing eumycetoma: report of two cases and comprehensive review of the literature. Mycoses. 2017;60:204–12.CrossRefPubMedGoogle Scholar
  4. 4.
    Tirado-Sánchez A, Calderón L, Saúl A, et al. Mycetoma: experience of 482 cases in a single center in Mexico. PLoS Negl Trop Dis. 2014;8:e3102.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Nenoff P, van de Sande WWJ, Fahal A, et al. Eumycetoma and actinomycetoma—an update on causative agents, epidemiology, pathogenesis, diagnostics and therapy. J Eur Acad Dermatol Venereol. 2015;29:1873–83.CrossRefPubMedGoogle Scholar
  6. 6.
    Queiroz-Telles F, de Hoog S, Santos DW, et al. Chromoblastomycosis. Clin Microbiol Rev. 2017;30:233–76.CrossRefPubMedGoogle Scholar
  7. 7.
    Gomes RR, Vicente VA, Azevedo CM, et al. Molecular epidemiology of agents of human chromoblastomycosis in Brazil with the description of two novel species. PLoS Negl Trop Dis. 2016;10:e0005102.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Radouane N, Hali F, Khadir K et al. [Generalized chromomycosis caused by Phialophora verrucosa]. Ann Dermatol Venereol. 2013;140:197–201.Google Scholar
  9. 9.
    Lima AM, Sacht GL, Paula LZ, et al. Response of chromoblastomycosis to voriconazole. An Bras Dermatol. 2016;91:679–81.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Milby AH, Pappas ND, O’Donnell J, et al. Sporotrichosis of the upper extremity. Orthopedics. 2010;33(4) doi: 10.3928/01477447-20100225-27.Google Scholar
  11. 11.
    Gremião ID, Miranda LH, Reis EG, et al. Zoonotic epidemic of sporotrichosis: cat to human transmission. PLoS Pathog. 2017;13:e1006077.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Chakrabarti A, Bonifaz A, Gutierrez-Galhardo MC, et al. Global epidemiology of sporotrichosis. Med Mycol. 2015;53:3–14.CrossRefPubMedGoogle Scholar
  13. 13.
    McGuinness SL, Boyd R, Kidd S, et al. Epidemiological investigation of an outbreak of cutaneous sporotrichosis, Northern Territory, Australia. BMC Infect Dis. 2016;16:16.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Mahajan VK. Sporotrichosis: an overview and therapeutic options. Dermatol Res Pract. 2014;2014:272376.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Marques GF, Martins AL, Sousa JM, et al. Characterization of sporotrichosis cases treated in a dermatologic teaching unit in the state of São Paulo—Brazil, 2003–2013. An Bras Dermatol. 2015;90:273–5.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    de Lima Barros MB, Schubach AO, de Vasconcellos Carvalhaes de Oliveira R, et al. Treatment of cutaneous sporotrichosis with itraconazole—study of 645 patients. Clin Infect Dis. 2011;52:e200–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Biancheri D, Kanitakis J, Bienvenu AL, et al. Cutaneous cryptococcosis in solid organ transplant recipients: epidemiological, clinical, diagnostic and therapeutic features. Eur J Dermatol. 2012;22:651–7.PubMedGoogle Scholar
  18. 18.
    Nenoff P, Reinel D, Krüger C, et al. Tropical and travel-related dermatomycoses: Part 2: cutaneous infections due to yeasts, moulds, and dimorphic fungi. Hautarzt. 2015;66:522–32.CrossRefPubMedGoogle Scholar
  19. 19.
    Srivastava GN, Tilak R, Yadav J et al. Cutaneous Cryptococcus: marker for disseminated infection. BMJ Case Rep. 2015;2015. pii: bcr2015210898.Google Scholar
  20. 20.
    Wang J, Bartelt L, Yu D, et al. Primary cutaneous cryptococcosis treated with debridement and fluconazole monotherapy in an immunosuppressed patient: a case report and review of the literature. Case Rep Infect Dis. 2015;2015:131356.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Tsuji G, Matsuda T, Shigyo A, et al. Primary cutaneous cryptococcosis successfully managed by surgical debridement and liposomal amphotericin B/flucytosine therapy. Eur J Dermatol. 2017;27:96–7.PubMedGoogle Scholar
  22. 22.
    Lortholary O, Fernández-Ruiz M, Perfect JR. The current treatment landscape: other fungal diseases (cryptococcosis, fusariosis and mucormycosis). J Antimicrob Chemother. 2016;71(suppl 2):ii31–6.Google Scholar
  23. 23.
    Gugnani HC, Muotoe-Okafor F. African histoplasmosis: a review. Rev Iberoam Micol. 1997;14:155–9.PubMedGoogle Scholar
  24. 24.
    Gugnani HC. Histoplasmosis in Africa: a review. Indian J Chest Dis Allied Sci. 2000;42:271–7.PubMedGoogle Scholar
  25. 25.
    Ravindran S, Sobhanakumari K, Celine M, et al. African histoplasmosis: the first report of an indigenous case in India. Int J Dermatol. 2015;54:451–5.CrossRefPubMedGoogle Scholar
  26. 26.
    Diadie S, Diatta B, Ndiaye M, et al. Multifocal histoplasmosis due to Histoplasma capsulatum var. duboisii in a 22 year-old Senegalese patient without proven immunodepression. J Mycol Med. 2016;26:265–70.CrossRefPubMedGoogle Scholar
  27. 27.
    Zida A, Niamba P, Barro-Traoré F, et al. Disseminated histoplasmosis caused by Histoplasma capsulatum var. duboisii in a non-HIV patient in Burkina Faso. J Mycol Med. 2015;25:159–62.CrossRefPubMedGoogle Scholar
  28. 28.
    Richaud C, Chandesris MO, Lanternier F, et al. Imported African histoplasmosis in an immunocompetent patient 40 years after staying in a disease-endemic area. Am J Trop Med Hyg. 2014;91:1011–4.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Raselli C, Reinhart WH, Fleisch F. Histoplasmosis—an unusual African souvenir. Dtsch Med Wochenschr. 2013;138:313–6.CrossRefPubMedGoogle Scholar
  30. 30.
    Gonçalves D, Ferraz C, Vaz L. Posaconazole as rescue therapy in African histoplasmosis. Braz J Infect Dis. 2013;17:102–5.CrossRefPubMedGoogle Scholar
  31. 31.
    Motswaledi HM, Monyemangene FM, Maloba BR. Blastomycosis: a case report and review of the literature. Int J Dermatol. 2012;51:1090–3.CrossRefPubMedGoogle Scholar
  32. 32.
    Smith RJ, Boos MD, Burnham JM, et al. Atypical cutaneous blastomycosis in a child with juvenile idiopathic arthritis on infliximab. Pediatrics. 2015;136:e1386–9.Google Scholar
  33. 33.
    Bonifaz A, Vázquez-González D, Perusquía-Ortiz AM. Endemic systemic mycoses: coccidioidomycosis, histoplasmosis, paracoccidioidomycosis and blastomycosis. J Dtsch Dermatol Ges. 2011;9:705–14.PubMedGoogle Scholar
  34. 34.
    Bonifaz A, Morales D, Morales N, et al. Cutaneous blastomycosis. An imported case with good response to itraconazole. Rev Iberoam Micol. 2016;33:51–4.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Laboratory for Medical MicrobiologyMölbisGermany
  2. 2.Department of MicrobiologyZagazig UniversityCairoEgypt
  3. 3.Department of DermatologyMbarara University of Science and TechnologyMbararaUganda

Personalised recommendations